Neurocrine for sale?

Quote
anonymous said:
Austedo grew at 28% 815 million last year Ingrezza grew at 15% $1.1Billion. Austedo did not have a designated sales force the first 18 months when launched at the same time as Ingrezza. Why would they? they were selling Copaxone $4.1 billion a year drug. What has help Ingrezza is that they got a head start on coverage... but look at your last shareholder report. Ingrezza is about to fall off the largest medicaid plan in the country. It is also the home state of Neurocrine. Losing Medi-Cal is a big problem for Neurocine. Your big drug as you like to put it just lost 16% of its Ingrezza business. You also are slipping on coverage in other markets to Austedo which is now covered on average 96% of all plans across the US (MedD, Commercial and medicaid). Ingrezza slipped to 90% from 94%. You have a new indication coming out for HD but Austedo has Orphan status until March/May 2023. Who knows by that time Austedo will probably be once a day while you guys come out with 20mg to help deal with all the drug interaction issues Ingrezza has due to front loading. Ingrezza has a horrible AE profile. Lets face it Ingrezza is a dirty drug. Look at the PI section 2.4 and 7,1. It is part of the reason why Neurocrine stock was at $132 a share now is $84 a share. You look at your shareholder report and you can see your company is testing the markets for a sale. Not to say they will, but they are looking. Maybe they want to sell just a few products and not the whole company...we will see. But that would explain hiring LTC reps at a time LTCs will not allow reps in, and hiring Neuro reps 18 months before you have an indication for HD and shrinking formulary coverage nationally. Maybe Neurocrine is not investing money in expanding formulary coverage because it is selling the drug? Take that money and hire a sales force to drive up value of the company to sell. Then "displace" those just hired. Also bring them on to buy or receive stock options. This will help to temporarily inflate stock value. I mean why not, its not like you will have to pay out vested 401k money to employees if they have been there less then 3 yrs. Seriously, you can call me bitter, but your company has no debt and your stock has dropped 37% in less then 2yrs. Your company is cutting its investments in many of its drugs. So it is possible it is trying to sell its pipeline, but it is looking more and more like Neurocrine is gonna be brought by someone. If I had to bet, it will be J&J or Pfizer. But dont rule out Lilly. I say this because they have already stated in their shareholder reports they want to acquire more neuroscience products to grow their pipelines which are thin. These companies have the capital and Neurocrine has not debt. Only thing that would hold things up is Ingrezzas AE profile and LTC lawsuits. Companies may not want to deal with the lawsuits of dirty drugs. Look at what happened to companies that sold Opioids. They were acquired and now those companies that brought them has to deal with the lawsuits. So, the lawsuits could save Neurocrine. We will have to wait and see. I would bet that there is a 70% chance you guys are brought in 6 months.
Click to expand...
Ok, I work for Neurocrine and a colleague just texted me to come on here and look at this post. This does make a lot sense and scares the hell out of me since I just accepted one of this sales roles less than 2 months ago. I certainly hope for the sake of my family as well as my future job prospects here at Neurocrine, that I wasn't sold a bill of goods?
 






anonymous said:
Ok, I work for Neurocrine and a colleague just texted me to come on here and look at this post. This does make a lot sense and scares the hell out of me since I just accepted one of this sales roles less than 2 months ago. I certainly hope for the sake of my family as well as my future job prospects here at Neurocrine, that I wasn't sold a bill of goods?
Click to expand...

Should have been more clear eyed coming into this. People are our most disposable asset. If you're banded 1 through 4, your goals are fundamentally incompatible with those calling the shots. What's the severance for a change in control, 6-mo?
 






anonymous said:
Should have been more clear eyed coming into this. People are our most disposable asset. If you're banded 1 through 4, your goals are fundamentally incompatible with those calling the shots. What's the severance for a change in control, 6-mo?
Click to expand...

I think the law requires 60 days notice of being laid off. Let's face it, in this industry we could all be laid off tomorrow with no notice. Standard package is at least 3 months pay if you been with a company less then 2 yrs
 






This makes sense. Why over pay teva reps to come here? I know most of these reps were high performers at teva, but it is not like they are gonna just convince austedo writers they convinced to write and switch back to Ingrezza. This whole thing looks bad. I am worried too because I am on the west coast and heard about Medicaid in California back in Dec. How do we lose Medicaid coverage in our HQ state?!
 






anonymous said:
Austedo grew at 28% 815 million last year Ingrezza grew at 15% $1.1Billion. Austedo did not have a designated sales force the first 18 months when launched at the same time as Ingrezza. Why would they? they were selling Copaxone $4.1 billion a year drug. What has help Ingrezza is that they got a head start on coverage... but look at your last shareholder report. Ingrezza is about to fall off the largest medicaid plan in the country. It is also the home state of Neurocrine. Losing Medi-Cal is a big problem for Neurocine. Your big drug as you like to put it just lost 16% of its Ingrezza business. You also are slipping on coverage in other markets to Austedo which is now covered on average 96% of all plans across the US (MedD, Commercial and medicaid). Ingrezza slipped to 90% from 94%. You have a new indication coming out for HD but Austedo has Orphan status until March/May 2023. Who knows by that time Austedo will probably be once a day while you guys come out with 20mg to help deal with all the drug interaction issues Ingrezza has due to front loading. Ingrezza has a horrible AE profile. Lets face it Ingrezza is a dirty drug. Look at the PI section 2.4 and 7,1. It is part of the reason why Neurocrine stock was at $132 a share now is $84 a share. You look at your shareholder report and you can see your company is testing the markets for a sale. Not to say they will, but they are looking. Maybe they want to sell just a few products and not the whole company...we will see. But that would explain hiring LTC reps at a time LTCs will not allow reps in, and hiring Neuro reps 18 months before you have an indication for HD and shrinking formulary coverage nationally. Maybe Neurocrine is not investing money in expanding formulary coverage because it is selling the drug? Take that money and hire a sales force to drive up value of the company to sell. Then "displace" those just hired. Also bring them on to buy or receive stock options. This will help to temporarily inflate stock value. I mean why not, its not like you will have to pay out vested 401k money to employees if they have been there less then 3 yrs. Seriously, you can call me bitter, but your company has no debt and your stock has dropped 37% in less then 2yrs. Your company is cutting its investments in many of its drugs. So it is possible it is trying to sell its pipeline, but it is looking more and more like Neurocrine is gonna be brought by someone. If I had to bet, it will be J&J or Pfizer. But dont rule out Lilly. I say this because they have already stated in their shareholder reports they want to acquire more neuroscience products to grow their pipelines which are thin. These companies have the capital and Neurocrine has not debt. Only thing that would hold things up is Ingrezzas AE profile and LTC lawsuits. Companies may not want to deal with the lawsuits of dirty drugs. Look at what happened to companies that sold Opioids. They were acquired and now those companies that brought them has to deal with the lawsuits. So, the lawsuits could save Neurocrine. We will have to wait and see. I would bet that there is a 70% chance you guys are brought in 6 months.
Click to expand...
Spot on post!
 






























anonymous said:
Now that BIIB took over Syndesi, I guess they won't be cleaning up this mess.
Click to expand...

Typical cring-er, wrong information and just by lunch got to the right place. Abvie acquired Syndesi. BIIB is busy cutting staff. Given what they think of Al's judgment I don't think they'll be a buyer.

Seeking Alpha reported Neurocrine Biosciences cut to neutral at Piper on growth trajectory of Ingrezza
Absent a sale of the company to a strategic buyer where there is overlapping commercial infrastructure (and hence a chock-full of operating synergies), shares are unlikely to appreciate considerably,"
​
We all see the cost synergies. I don't see any on the revenue side. So work hard to make your numbers, if you do a good job someone might just buy it out and lay you off (again).
 






anonymous said:
Typical cring-er, wrong information and just by lunch got to the right place. Abvie acquired Syndesi. BIIB is busy cutting staff. Given what they think of Al's judgment I don't think they'll be a buyer.

Seeking Alpha reported Neurocrine Biosciences cut to neutral at Piper on growth trajectory of Ingrezza
Absent a sale of the company to a strategic buyer where there is overlapping commercial infrastructure (and hence a chock-full of operating synergies), shares are unlikely to appreciate considerably,"
​
We all see the cost synergies. I don't see any on the revenue side. So work hard to make your numbers, if you do a good job someone might just buy it out and lay you off (again).
Click to expand...

Yeah yeah yeah, and Goldman Sachs upgraded NBIX to a Buy.
 












anonymous said:
If your read Goldman's justification, they make the same point:
genuine strategic optionality (i.e., the company is well-positioned to build their asset base through strategic business development activities, and itself could also reasonably be considered an acquisition target).
Click to expand...

You really really need to find a hobby dude, your bitterness towards Neurocrine isn't healthy.
 
















































Top Bottom
Back
Quote